The Parathyroids (3^rd Ed.)
Basic and Clinical Concepts

The third edition of The Parathyroids, led by a new stellar editorial team, has been thoroughly updated to reflect the considerable advances in just about every aspect of PTH biology over the past decade. It continues to be the authoritative reference that spans the basic science of parathyroid hormone treatment to major clinical disorders in a superb, single compendium. This translational resource is invaluable to graduate students, fellows, researchers, and research clinicians in the fields of endocrinology, bone biology, osteology, and rheumatology.

• Contains chapters and information on noninvasive imaging, fracture healing, secondary diseases such as CKD, Vitamin D, cell signaling pathways, vascular calcification, as well as advances in genetics/genomics
• Includes essential updates on the critical importance of Vitamin D insufficiency and its relationship to secondary hyperparathyroidism
• Offers new insights into the underlying mechanisms of parathyroid hormone actions on osteocytes and sclerostin
• Examines essential updates in the understanding of secondary hyperparathyroidism associated with chronic kidney disease, facture healing, and vascular disease

Introduction/History Chapter

Section I: Molecular, Cellular, and Physiologic Aspects of the Parathyroids

Section II: Clinical Aspects of Primary Hyperparathyroidism

Section III: Non-Parathyroid Hypercalcemic States

Section VI: Secondary and Tertiary Hyperparathyroid States

Section V: The Hypoparathyroid States

Section VI: The Parathyroids and Osteoporosis

Students, researchers, fellows, and professionals in endocrinology and bone/mineral research

Dr. John P. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the NIH in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach.
Dr. Marcus is Professor-Emeritus, Stanford University, where he served on the full-time medical faculty for almost 25 years, before joining the Emeritus faculty in 2001. At Stanford, he was located at the Veterans Affairs Medical Center, Palo Alto California, where he served as Director of the Aging Study Unit of the Geriatrics Research, Education, & Clinical Center from 1982-2001. Dr. Marcus enjoyed a long career as a clinical investigator in the fields of bone and mineral metabolism and osteoporosis medicine. His own research interests included diagnosis and therapy of primary hyperpara-thyroidism, interactions of the parathyroid-vitamin D axis with estrogen, age-related changes in the growth hormone-IGF axis, effects of growth hormone replacement for older men and women, metabolic and musculoskeletal effects of resistance exercise in older men and women, adolescent bone acquisition, and osteoporosis therapeutics. Dr. Marcus’ laboratory was a study site for many of the pivotal clinical trials in the osteoporosis field. These include the NIH Post-menopausal Estrogen/Progestin Interventions Trial (PEPI), Merck’s Fracture Intervention Trial (FIT), Lilly’s Multiple Outcomes of Raloxifene Intervention (MORE